odanacatib

Small moleculeexperimental

Odanacatib is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption. — Wikipedia

Clinical trial activity

21 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
13
Phase 3
7
Phase 4
0

Earliest trial started Jun 1, 2004 (NCT00863590)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1
Mol. weight
525.57 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • l-1037536
  • mk0822
  • mk0822
  • mk-0822
  • mk-0822
  • mk-0822
  • mk-0822
  • odanacatib
  • odanacatib
  • odanacatib
  • odanacatib
  • odanacatib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01803607Phase 3Mar 1, 2013Merck
NCT01630616Phase 1Mar 1, 2013Merck
NCT01552122Phase 3May 1, 2012Merck
NCT01512693Phase 1Feb 1, 2012Merck
NCT01512667Phase 1Jan 1, 2012Merck
NCT01120600Phase 3Jun 1, 2010Merck
NCT01068262Phase 1Dec 8, 2009Merck
NCT00885170Phase 2Apr 1, 2009Merck
NCT00729183Phase 3Oct 1, 2008Merck
NCT00691899Phase 3Sep 1, 2008Merck
NCT00692458Phase 3Sep 1, 2008Merck
NCT00620113Phase 2Dec 1, 2007Merck
NCT00529373Phase 3Sep 1, 2007Merck
NCT00399802Phase 2Nov 1, 2006Merck
NCT00397683Phase 2Oct 1, 2006Merck
NCT00242476Phase 2Sep 1, 2005Merck
NCT00112437Phase 2Jun 1, 2005Merck
NCT00863525Phase 1Nov 1, 2004Merck
NCT00770159Phase 1Nov 1, 2004Merck
NCT00769418Phase 1Sep 1, 2004Merck
Showing 20 of 21 trials
Page 1 / 2

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit212132004
1 organizations
Page 1 / 1